PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer (PATRON)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04557501|
Recruitment Status : Recruiting
First Posted : September 21, 2020
Last Update Posted : July 21, 2021
Through the conduct of a Phase III randomized controlled trial, investigators plan to: 1) determine if PSMA PET/CT guided intensification of radiotherapy or surgery improves cancer outcomes compared to conventional imaging-guided therapy in patients at risk of advanced disease, 2) evaluate its impact on toxicity and quality of life, and 3) measure the cost-effectiveness of the PSMA PET/CT guided approach.
Participants with high-risk prostate cancer planned for curative-intent standard-of-care radiotherapy or surgery, or with biochemical failure after radical prostatectomy planned for salvage radiotherapy will be enrolled over 3 years (n=776). Those randomized to the investigational arm will have PSMA PET/CT prior to therapy. Based on the imaging results, treating physicians will intensify radiotherapy or surgery unless widely metastatic disease is found, in which case systemic therapy will be intensified.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Diagnostic Test: PSMA PET/CT guided intensification of therapy Other: Control Arm||Phase 3|
PSMA PET/CT, particularly with the new generation [18F]DCFPyL radiotracer, has substantially improved our ability to detect sites of prostate cancer compared with conventional imaging alone. When combined with innovative radiotherapeutic and surgical techniques that can now safely target and ablate such disease sites, next generation imaging is now poised to transform the therapeutic paradigm for patients at risk of advanced cancer.
Investigators postulate that intensification of radiotherapy or surgery based on the results of PSMA PET/CT will improve cancer control outcomes in a cost-effective manner, with minimal toxicity, and an overall improvement in quality of life in the longer term.
Investigators expect to show that PSMA PET/CT will have a direct and profound impact on radiotherapy and surgery practice, translating to improved failure-free survival outcomes in patients at risk of advanced prostate cancer. The subset of patients potentially impacted is broad, including patients recurring after prostatectomy and newly presenting patients with high-risk features. Although PSMA PET/CT is increasingly making its way into clinical practice around the world, Canadian provinces will need to make an informed decision of whether to fund this imaging for our patients. The high-level evidence gathered in this trial is desperately needed to assess the impact on patient outcomes and, in doing so, justify broad access and reimbursement for patients with prostate cancer.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||776 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer|
|Actual Study Start Date :||January 6, 2021|
|Estimated Primary Completion Date :||October 2028|
|Estimated Study Completion Date :||October 2028|
Active Comparator: Control - SOC Treatment
Participants to receive surgery or radiotherapy (+/- hormone therapy) as planned per SOC.
Other: Control Arm
Control - Treatment without PSMA PET/CT
Experimental: Experimental - PSMAiTx
Participants undergo PSMA PET/CT prior to treatment, and treated intensified based on image findings.
Diagnostic Test: PSMA PET/CT guided intensification of therapy
PSMA PET/CT prior to treatment.
- To determine if PSMA PET/CT guided intensification of therapy is superior to standard of care (SOC) therapy as measured by improved failure-free survival (FFS). [ Time Frame: 5 years ]
- Rates of toxicity (CTCAE) [ Time Frame: 5 years ]
- Time to subsequent next-line therapy [ Time Frame: 5 years ]
- Quality of Life (EPIC 26) [ Time Frame: 5 years ]
- New lesion detection yield (on PSMA PET/CT) [ Time Frame: 3 years ]
- Impact of PMSA PET/CT on RT or surgical management (rate of treatment intensification) [ Time Frame: 3 years ]
- Cost-effectiveness (EQ5D5L) [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04557501
|Contact: Cindy Prieemail@example.com|
|Contact: Cynthia Ménardfirstname.lastname@example.org|
|CHU de Québec||Recruiting|
|Québec, Quebec, Canada|
|Contact: Josee Allard email@example.com|
|Contact: Sophie Pouliot firstname.lastname@example.org|
|Principal Investigator: Eric Vigneault, MD|
|Sherbrooke, Quebec, Canada, J1H 5H3|
|Contact: Elsie Morneau 819-346-1110 x12827 email@example.com|
|Contact: Sophie Couture 819-346-1110 x14311 firstname.lastname@example.org|
|Principal Investigator: Patrick Richard, MD|
|Contact: Cindy Prie 514-655-0390 email@example.com|
|Principal Investigator: Cynthia Menard, MD|